pentobarbital will lower the extent or effect of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Solid or average CYP3A inducers may possibly minimize cobimetinib systemic exposure by >eighty% and lessen its efficacy.pentobarbital will decrease the level or effect of budesonide by aff